# ThromboGenics clinical trials: 28 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials with ThromboGenics as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by ThromboGenics: 28 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/thrombogenics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 13, 2018 | NCT03669393 | A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1) | ThromboGenics | Phase 2 | Completed | Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03669393) |
| September 12, 2018 | NCT03666923 | A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME) | ThromboGenics | Phase 1 | Completed | Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03666923) |
| April 30, 2018 | NCT03511898 | A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME) | ThromboGenics | Phase 1 | Completed | Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03511898) |
| March 6, 2017 | NCT03071068 | A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME) | ThromboGenics | Phase 2 | Completed | Diabetic Retinopathy, Macular Edema | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03071068) |
| February 12, 2016 | NCT02681809 | A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR | ThromboGenics | Phase 2 | Terminated | Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02681809) |
| July 18, 2014 | NCT02193945 | A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA | ThromboGenics | Observational | Completed | Symptomatic Vitreomacular Adhesion (VMA) | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02193945) |
| March 6, 2014 | NCT02079883 | Ocriplasmin Research to Better Inform Treatment (ORBIT) | ThromboGenics | Observational | Completed | Symptomatic Vitreomacular Adhesion | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02079883) |
| September 7, 2011 | NCT01429441 | Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole | ThromboGenics | Phase 3 | Completed | Vitreomacular Adhesion Including Macular Hole | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01429441) |
| April 29, 2011 | NCT01344954 | Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery | ThromboGenics | Phase 2 | Completed | Prophylaxis of Venous Thromboembolic Events | 632 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01344954) |
| February 2, 2011 | NCT01287988 | Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin... | ThromboGenics | Observational | Completed | Symptomatic Vitreomacular Adhesion | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01287988) |
| July 9, 2010 | NCT01159665 | The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana... | ThromboGenics | Phase 2 | Completed | Vitrectomy | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01159665) |
| January 25, 2010 | NCT01055535 | Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion | ThromboGenics | Phase 2 | Completed | Focal Vitreomacular Adhesion | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01055535) |
| September 29, 2009 | NCT00986362 | Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy | ThromboGenics | Phase 2 | Completed | Vitrectomy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00986362) |
| June 4, 2009 | NCT00913744 | Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion | ThromboGenics | Phase 2 | Completed | Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00913744) |
| November 26, 2008 | NCT00798317 | Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. | ThromboGenics | Phase 3 | Completed | Vitreomacular Adhesion | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00798317) |
| November 19, 2008 | NCT00793234 | Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery | ThromboGenics | Phase 2 | Completed | Total Knee Replacement Surgery | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00793234) |
| October 29, 2008 | NCT00781859 | Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. | ThromboGenics | Phase 3 | Completed | Vitreomacular Adhesion | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00781859) |
| February 20, 2008 | NCT00618579 | Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin | ThromboGenics | Phase 1 | Completed | Healthy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00618579) |
| February 11, 2008 | NCT00612417 | Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402 | ThromboGenics | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00612417) |
| February 11, 2008 | NCT00612196 | A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers | ThromboGenics | Phase 1 | Completed | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00612196) |
| February 15, 2007 | NCT00435539 | A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) | ThromboGenics | Phase 2 | Completed | Vitreomacular Traction | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00435539) |
| January 29, 2007 | NCT00428129 | Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT | ThromboGenics | Phase 2 | Terminated | Deep Vein Thrombosis | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00428129) |
| December 19, 2006 | NCT00412958 | A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III) | ThromboGenics | Phase 2 | Completed | Vitrectomy | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00412958) |
| December 18, 2006 | NCT00412451 | A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic... | ThromboGenics | Phase 2 | Completed | Diabetic Macular Edema | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00412451) |
| July 22, 2005 | NCT00123305 | Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke | ThromboGenics | Phase 2 | Completed | Stroke, Acute | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00123305) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 17 |
| Phase 3 | 3 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Terminated | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetic Retinopathy | 5 |
| Diabetes Mellitus | 2 |
| Stroke | 2 |
| Retinal Telangiectasis | 1 |
| Idiopathic Juxtafoveal Retinal Telangiectasia | 1 |
| Arterial Occlusive Diseases | 1 |
| Thromboembolism | 1 |
| Venous Thrombosis | 1 |
| Vitreous Detachment | 1 |
| Disease Progression | 1 |
| Macular Degeneration | 1 |
| Ischemic Stroke | 1 |
| Macular Edema | 1 |
| Eye Diseases | 1 |
| Retinal Perforations | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B radio and television commercials companies in the United States](https://specstream.ai/data/businesses/b2b-radio-and-television-commercials-companies/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Pediatric anesthesiology practices in the United States](https://specstream.ai/data/businesses/pediatric-anesthesiology-practices/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Dermatology practices in the United States](https://specstream.ai/data/businesses/dermatology-practices/united-states)
- [Logging companies in the United States](https://specstream.ai/data/businesses/logging-companies/united-states)
